IP Library Granted Patent US 9,187,501
Granted Patent B2
US 9,187,501 · App. 14/011,488 · Granted Nov 17, 2015

Nitric oxide-releasing nanorods and their methods of use

Inventors: Mark H. Schoenfisch (Chapel Hill, NC); Yuan Lu (Chapel Hill, NC)
Assignee: The University of North Carolina at Chapel Hill
C07F7/0834A01N59/00A61K47/48869A61K49/1884B82Y5/00Y10T428/2975
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,187,501
App. No.
14/011,488
Granted
Nov 17, 2015
Kind
B2
Abstract

In one aspect, the subject matter disclosed herein is directed to NO-releasing functionalized nanorods having a desirable aspect ratio. The nanorods are also capable of releasing a desirable amount of NO (nitric oxide). In another aspect, the subject matter disclosed herein is directed to a composition comprising the NO-releasing nanorods. In another aspect, the subject matter disclosed herein is directed to methods of preparing NO-releasing nanorods having a specified aspect ratio. In another aspect, the subject matter disclosed herein is directed to a method of combating infection comprising administering to a subject a composition comprising NO-releasing nanorods, wherein the nanorods have a specified aspect ratio and NO-release profile.

Claims (33)

1. A nitric oxide-releasing nanorod comprising,

i. a silane, and

ii. a functionalized mono, di or trialkoxysilane,

wherein said functionalized mono, di or trialkoxysilane comprises a NO-donor molecule;

wherein said nanorod has an aspect ratio of at least 1 and a [NO] max in a range of about 10 ppb/mg to about 16,000 ppb/mg.

2. The nanorod of claim 1 , wherein said nanorod is mesoporous.

3. The nanorod of claim 2 , wherein said mesoporous nanorod comprises pores having sizes from about 2 nm to about 50 nm in diameter.

4. The nanorod of claim 1 , wherein said silane has the formula Si(OR) 4 , wherein R is a C 1-5 alkyl.

5. The nanorod of claim 4 , wherein said silane is TEOS or TMOS.

6. The nanorod of claim 1 , wherein said silane is selected from the group consisting of methyltrimethoxysilane (MTMOS), ethyltrimethoxysilane (ETMOS), butyltrimethoxysilane (BTMOS), propyltrimethoxysilane (PTMOS), butyltriethoxysilane (BTEOS), and octadecyltrimethoxysilane (ODTMOS).

7. The nanorod of claim 4 , wherein said functionalized mono, di or trialkoxysilane is a nitric oxide functionalized N-(2-aminoethyl)-3-amino-isobutyl-dimethylmethoxysilane (AEAI); aminopropyldimethylethoxysilane (APDE); N-(6-aminohexyl)aminopropyltrimethoxysilane (AHAP3); N-(2-aminoethyl)-3-aminopropyltrimethoxysilane (AEAP3); (3-trimethoxysilylpropyl)di-ethylenetriamine (DET3); (aminoethylaminomethyl)phenethyltrimethoxysilane (AEMP3); [3-(methylamino)propyl]trimethoxysilane (MAP3); N-butylamino-propyltrimethoxysilane(n-BAP3); t-butylamino-propyltrimethoxysilane(t-BAP3); N-ethylaminoisobutyltrimethoxysilane(EAiB3); N-phenylamino-propyltrimethoxysilane (PAP3); and N-cyclohexylaminopropyltrimethoxysilane (cHAP3).

8. The nanorod of claim 1 , wherein said aspect ratio is from about 4 to about 12.

9. The nanorod of claim 1 , wherein said aspect ratio is about 8.

10. The nanorod of claim 1 , wherein said nanorod has a [NO] max of from about 10 ppb/mg to about 14,000 ppb/mg.

11. The nanorod of claim 1 , wherein said nanorod has a [NO] max of from about 3,000 ppb/mg to about 7,000 ppb/mg.

12. The nanorod of claim 1 , wherein said nanorod has a length of less than about 1,700 nm.

13. The nanorod of claim 1 , wherein said nanorod has a length of from 100 nm to about 1,300 nm.

14. The nanorod of claim 1 , further comprising —(CH 2 CH 2 O) x — that is covalently bound to said functionalized mono, di, or trialkoxysilane, wherein x is an integer from one to 10,000.

15. The nanorod of claim 14 , wherein x is an integer from one to 50.

16. The nanorod of claim 1 , wherein said NO donor is selected from the group consisting of a diazeniumdiolate, nitrosothiol, a nitrosamine, a hydroxyl nitrosamine, a hydroxyl amine, a hydroxyurea, and combination thereof.

17. The nanorod of claim 16 , wherein said NO donor is selected from the group consisting of a diazeniumdiolate.

18. A method of preparing the nitric oxide-releasing nanorod of claim 1 , comprising:

a. contacting a silane with ammonia, sodium acetate, potassium acetate, sodium hydroxide or potassium hydroxide and mixtures thereof in the presence of a surfactant at a temperature T 1 ; to form a first composition;

b. allowing said first composition to age for a period of time, P, at a temperature T 2 to form a nanorod;

c. harvesting said nanorod;

d. contacting said harvested nanorod with a mono, di or trialkoxylsilane at a temperature, T 3 , to form an amine-functionalized nanorod;

e. harvesting said amine-functionalized nanorod;

f. contacting said harvested amine-functionalized nanorod with NO gas to form a nitric-oxide releasing nanorod; and

g. harvesting said nitric-oxide releasing nanorod.

19. A method of delivering nitric oxide to a subject, comprising:

administering an effective amount of said nitric oxide-releasing nanorod of claim 1 to said subject.

20. A method of treating a bacterial infection in a subject, comprising:

administering an effective amount of said nitric oxide-releasing nanorod of claim 1 to a subject in need thereof.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
To: LIGAND PHARMACEUTICALS INCORPORATED
Reel/Frame 070776/0692 →
CORRECTION BY DECLARATION ERRONEOUSLY FILED AGAINST REEL 066350/FRAME 0942 Recorded Nov 12, 2024
From: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
To: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Reel/Frame 069386/0419 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2024
From: NOVAN, INC.
To: LNHC, INC.
Reel/Frame 066350/0942 →
SECURITY INTEREST Recorded Oct 18, 2023
From: CYDEX PHARMACEUTICALS, INC.; LIGAND PHARMACEUTICALS INCORPORATED; METABASIS THERAPEUTICS, INC.; PFENEX INC.
To: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065271/0025 →
CONFIRMATORY LICENSE Recorded Oct 28, 2013
From: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031499/0173 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2013
From: SCHOENFISCH, MARK H.; LU, YUAN
To: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Reel/Frame 031106/0323 →
Continuity (2)
Provisional Application 61694007 · Aug 28, 2012
Related Publication 20140065200A1 · Mar 6, 2014